Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Non–Small-Cell Lung Cancer in China

Objective: Camrelizumab is the first domestic PD-1inhibitor approved to be combined with chemotherapy as a first-line therapy for advanced nonsquamous non–small-cell lung cancer (NSCLC) in China. The purpose of this study was to determine whether using camrelizumab in the first-line setting is cost-...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Liu Qiao, Zhen Zhou, Xiaohui Zeng, Chongqing Tan
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Frontiers Media S.A. 2021-11-01
Schriftenreihe:	Frontiers in Pharmacology
Schlagworte:	cost-effectiveness nonsquamous non–small-cell lung cancer camrelizumab pembrolizumab pemetrexed China
Online-Zugang:	https://www.frontiersin.org/articles/10.3389/fphar.2021.728440/full
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!